The Avon patello-femoral joint replacement : 2 to 18-year results of a large single centre cohort by Metcalfe, Andrew J. et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/106668                            
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
  
 
The Avon patello-femoral joint replacement: 2 to 18-year 
results of a large single centre cohort. 
 
Accepted authors manuscript for the Bone and Joint Journal 
https://online.boneandjoint.org.uk/journal/bjj 
 
A.J.Metcalfe2*  
N.Ahearn1,  
M.A.Hassaballa1,  
N.Parsons2,  
C.E.Ackroyd1,  
J.R. Murray1,  
J.Robinson1,  
J.D.Eldridge1,  
A.J.Porteous1.  
 
From: 
1. The Avon Orthopaedic Centre, Southmead Hospital, Bristol, BS10 5NB 
2. Warwick Medical School, Warwick University, Coventry, CV4 7AL 
 
 
*corresponding author 
 
email: a.metcalfe@warwick.ac.uk 
 
tel: 02476965064 (secretary: Kathy O’Malley) 
 
 
 
 
  
 
Abstract 
 
Aims 
This study reports on the medium to long-term implant survivorship and patient-reported outcomes 
for the Avon patello-femoral joint (PFJ) replacement.   
Patients and Methods 
558 Avon PFJ replacements in 431 patients, with minimum two-year follow-up, were identified from 
a prospective database. Patient-reported outcomes and implant survivorship were analysed, with 
follow-up of up to 18 years.  
Results 
Outcomes were recorded for 483 implants, representing an 86% follow-up rate. The median post-
operative Oxford Knee Score (0-48 scale) was 35 (IQR 25.5-43) and the median WOMAC (0-100 scale) 
was 35 (IQR 25-53) at two years. There were 105 revisions, 61 (58%) for progression of osteoarthritis. 
All documented revisions were to primary knee systems without augmentation. The implant survival 
rate was 77.3% at 10 years and 67.4% at 15 years. Cases performed in the later nine years of the study 
had a significantly (p=0.039) improved survival (91.8%) compared with those performed in the first 
nine years (78%). Regression analysis of explanatory data variable showed that the operating surgeon 
had the strongest effect on survivorship.  
Conclusion 
Good long-term results can be obtained with the Avon patello-femoral replacement, with 
maintenance of PROMs, acceptable survival and low rates of loosening and wear.   
 
  
  
Introduction 
Isolated patello-femoral osteoarthritis can cause significant disability and is common, affecting 
between 11 and 24% of the population with knee pain1. Several arthroplasty options have been 
developed with the aim of replacing the patello-femoral joint in isolation. Outcomes for various 
implants have been reported, with varying degrees of success, but these studies are limited in terms 
of the numbers of cases or length of follow up2-7.  
The Avon (Stryker Orthopaedics, Mahwah, New Jersey) patello-femoral joint (PFJ) replacement was 
introduced in 1996 with the aim of resolving some of the problems experienced with earlier designs2. 
The trochlear component has an onlay design. Its position, in terms of flexion, offset and external 
rotation is not defined by the native anatomy, which is often dysplastic8. Proximally there is a broad 
articulating trochlear surface that narrows and becomes more congruent in flexion, and the patella 
button has an offset dome design. The Avon has become one of the most popular designs for PFJ 
replacement worldwide, and has been the most common PFJ implant on the UK National Joint Registry 
(NJR) since its inception9. 
As the Avon Orthopaedic Centre, we have maintained a prospectively collected database of all cases 
performed since the introduction of the implant. This has been reported on previously, although in 
earlier publications the follow up was relatively short and the cohort represented the early group of 
patients treated with this device, without reference to current practice and indications2,3. 
The aim of this paper is to report on the long-term results of the Avon patello-femoral replacement 
over the full history of this large single-centre cohort, with minimum of 2-years and a maximum of 18-
years follow up.   
  
  
Patients and Methods 
This study was performed as a clinical effectiveness project and had formal approval from the local 
clinical governance department. The Avon patello-femoral database (Microsoft Access, Microsoft, 
USA) has been prospectively collected in Bristol since the implant was first introduced in 1996. All 
Avon patello-femoral replacements performed by any of the surgeons in the unit (private or NHS) 
were entered into the database which is managed and maintained by the Bristol Knee Group.  
Demographic data included: patient age, primary diagnosis, prior operations and (for cases of primary 
osteoarthritis) pattern of disease at surgery. Post-operatively, hard end-points were recorded 
including death and revision of the implants. The reason for revision and the implant used was 
documented and if a revision was performed in another centre, then the surgical team was contacted 
for details of the date and the reason for revision. The WOMAC score (expressed as a percentage, 0 
being the best score), and the Oxford Knee Score (OKS) (0-48, 48 being the best score) were collected 
pre-operatively and at one, two, five, eight, ten, twelve and fifteen years routinely10,11. Assessments 
were performed in clinic, however patients who did not attend clinic or were beyond 15 years since 
their operation were contacted by postal survey. Non-responders to postal contacts were followed up 
by a telephone interview. The dataset was comprehensively reviewed and updated with new postal 
and telephone follow-ups in 2014 and this paper represents a full analysis of those data, giving follow-
up for the longest surviving implants of 18 years. 
Only primary Avon patello-femoral replacements were included in the analysis. There were no other 
selection criteria and as such this represents a consecutive series. A minimum follow-up period of two 
years was set, based on previous studies showing that outcome after total knee replacement (TKR) 
cannot be fully determined until two years12.  
Data were extracted into Microsoft Excel (Microsoft, USA) and this was used to calculate medians, 
standard deviations and 95% confidence intervals for the outcome scores. The Kaplan-Meier method 
was used to determine implant survival. A Cox proportional hazard regression analysis was performed 
  
to examine the relationship between implant survival and explanatory data variables: patient age, 
gender, diagnosis at time of surgery, individual surgeon and implantations performed in the first and 
last 9 years of the study. This split of the cohort was to assess the difference in implant survival and 
outcome between the initial use of the implant and current, contemporary practice. Age groups were 
assigned as those under the age of 50, and then by decades up to the age of 80 and over. Surgeons 
who had performed over ten cases were given an anonymous numerical code to assess individual 
surgeon effects without assessing named individuals, and these data were analysed with strict 
anonymity. Diagnosis at operation was established from a list of options: lateral facet OA, medial facet 
OA, symmetrical OA, subluxation, dislocation, post-traumatic, anterior knee pain. The diagnosis of 
dysplasia was added in the last seven years of the cohort. Linear regression models were also fitted to 
assess the association between year two OKS and WOMAC scores and explanatory data variables; a 
stepwise backwards elimination algorithm was used to find the best subset of explanatory variables 
for each model. Two-year outcomes were chosen for this analysis as this has been shown to be the 
peak outcome achieved after total knee replacement12. The survival and regression analyses were 
performed using R13 and significance was set at the 5% level. Medians were used to summarise the 
PROMS data and the variability was quantified using the interquartile range, to allow comparability 
with PROMs data reported from the NJR14,15. 
  
  
Results 
There were 558 cases performed in 431 patients over the full two to eighteen-year series, of which 
357 cases in 268 patients were performed over ten years ago. There were 351 females and 80 males 
and the mean age was 58.8 (range 25-92). The mean age at time of surgery fell gradually over the 
course of the study, from 69.8 in the first year to 52.8 in the last year, as demonstrated in Figure 1.  
The outcome (defined as whether the implant had been revised or was known to be in situ) was 
determined in 483 cases representing an 86% rate of follow up. There were 73 deaths, none of which 
were known to be related to the procedure. With those who had died or been revised excluded, the 
outcome was determined in 295 of 370 cases, giving an 80% follow-up rate of surviving implants. 
There were 105 revisions in 93 patients. Four of the revisions were to further PFJ replacements (three 
to another Avon and one to a Smith and Nephew Journey), 90 revisions were to standard total knee 
replacements with no cases requiring stems, augments or revision implants. The revision implant used 
was unknown in 11 cases. The reasons for revision are documented in Table 1, the majority were for 
progression of osteoarthritis. The ten-year survival rate for the whole cohort was 77.3% (95% CI 72.4 
to 81.7%) and the fifteen-year survival rate was 67.4% (95% CI 57.1 to 74.3%) (Figure 2). The Cox 
proportional hazard regression analysis showed that age, gender and diagnosis had no effect on 
implant survival (p=0.218, p=0.245 and p=0.993 respectively from likelihood ratio tests). Comparison 
between the cohort with less than nine-year follow-up and the with nine to eighteen-year follow-up 
cohort was significant (p=0.039) and the effect of the individual surgeon was strong (p=0.001). Those 
cases performed within the last nine years had a 91.8% (95% CI; 66.5 to 97.1%) survival out to nine 
years as opposed to a 79.1% (95% CI; 74.7 to 83.6%) survival at nine years for the cases performed in 
the earlier half of the cohort. Data were sparse for the former group at longer follow-up times, so 
consequently confidence intervals were wide. 
The OKS (0-48) and WOMAC (0-100) scores for patients with surviving implants are given in Table 2. 
The median improvement in OKS was 16 points from 19 (IQR 14-26) pre-operatively to 35 (IQR 25.5-
  
43) at 2 years. The median WOMAC score improved by 27, from 62 (IQR 48-70) pre-operatively to 35 
(IQR 25-53) two years post-operatively. The improvement in scores was maintained over the fifteen-
year period of the study, with a median fifteen-year OKS of 35 (IQR 25-41.5) and a median WOMAC 
score of 37 (IQR 23-45).   
For both two-year OKS and WOMAC scores, there were two statistically significant explanatory 
variables in the regression models, age and diagnosis. For OKS p=0.036 for age group and p=0.004 for 
diagnosis group, and for WOMAC p=0.032 and p=0.013 respectively. Regression coefficient estimates 
for OKS are displayed in Figure 3. OKS and WOMAC models showed very similar patterns, due in large 
part to the strong correlation between these PROMS (-0.95; 95% CI -0.96 to -0.93). Overall model fits 
were very modest, accounting for only 10% and 13% of the variation the OKS and WOMAC scores 
respectively.  
With regard to age, the lowest outcome scores were seen in the under 50 age group, with scores in 
the age group 60-70 being the highest (Figure 3a). With regard to diagnosis, the worst scores occurred 
in those treated for anterior knee pain, medial facet OA and post-traumatic OA, whereas better scores 
were seen in those with lateral facet OA, dislocation and subluxation (Figure 3b).  
  
  
Discussion 
The Avon patello-femoral joint replacement has been in use in the Avon Orthopaedic Centre for over 
eighteen years and during that time it has been used by eleven different surgeons. Whilst this study 
includes patients from the designer surgeon, three quarters of the patients in the series were 
performed by non-designer surgeons and as such it represents a broader experience over a prolonged 
time period. To our knowledge this is the largest series of patello-femoral replacements outside of the 
registries with amongst the longest follow-up times in the literature. From these data, we can 
conclude that the Avon patello-femoral replacement can provide good functional outcomes, 
maintained over a prolonged period with acceptable survivorship, particularly if used with 
contemporary indications. 
The PROMs and variability found in this study are similar to those reported in the UK NJR for the Avon 
patello-femoral replacement. The one year post-operative OKS for our cohort was 35 compared to 34 
in the UK NJR14. Whilst these scores are similar to those reported for TKR, the patient populations are 
different in age, in pattern of disease and in symptoms. We did not capture PROMs that assess higher 
levels of function as the choice of measures was made at the start of data capture in 1996, before 
such measures (like KOOS or OKS-APQ) were widely available or reported on. Future studies and 
cohorts now being set up may wish to consider this in their design. 
Randomised controlled studies comparing PFJ replacement and TKR are currently being undertaken 
but have not yet been reported in the literature. The two-year results of a randomised trial comparing 
the Avon patello-femoral replacement to the PFC Sigma total knee replacement for isolated patello-
femoral osteoarthritis, blinded for the first post-operative year, were presented at the British 
Orthopaedic Association Congress in 201716. Superior patient reported outcomes were found for the 
arm who received the Avon replacement.   
In our study, the overall implant survival at ten years was 77.3.% This is comparable to 81.3% for 
patello-femoral replacements found in the UK NJR 2016 report9. We found that implant survivorship 
  
improved in the later half of the 18-year follow-up period, with nine-year survivorship of 91.8% for 
cases performed in the later 9 years. Refinements in surgical technique, instrumentation and surgical 
indications could all be responsible for the improved survivorship in the latter half of the cohort. With 
time and evolving experience with the implant, usage indications have gradually evolved. The decline 
in patient’s mean age at surgery throughout the study is indicative of this and probably reflects our 
increasing tendency over time to recommend PFJ replacement in younger patients with trochlea 
dysplasia or a history of patella instability. Whereas, in the early years, implant usage was restricted 
to older individuals with advanced disease.  
The individual surgeon was found to have the most significant impact on the revision rate. This could 
be the result of both patient selection and surgical technique. However, the difference seen in 
frequency of revisions for progression of osteoarthritis suggests that patient selection is likely to be 
the most important of these factors. Patient age was not a predictor of survival of the implant, but did 
have an effect on the outcome score at two years. The same pattern of lower scores in younger 
individuals has been noted for TKR previously and therefore is not unique to PFJ12,17. Again, this 
supports the need for further comparative trials in suitable patients where age groups are 
appropriately balanced. 
Diagnosis at the time of surgery was not found to be a significant factor in predicting implant survival. 
It was, however, influential for patient reported outcomes, with subluxation and dislocation being 
associated with better outcomes and anterior knee pain and post-traumatic disease being associated 
with poorer outcomes. Whilst the exact criteria for undertaking PFJ replacement may have varied 
between surgeons, the recommendation that patients should have full thickness chondral loss 
isolated to the patello-femoral joint has remained as a pre-requisite for surgery.   
The diagnosis of trochlear dysplasia was only entered into our database relatively recently as a 
separate diagnosis, and there were no formal criteria defined for this, which may explain why this did 
not affect outcomes in this study. It has previously been reported that a pre-operative diagnosis of 
  
dysplasia is associated with better results with PFJ replacement, presumably as this is a structural 
cause for single joint disease which is resolved by the replacement18. We did however note better 
outcomes in patients with subluxation and dislocation which are commonly associated with trochlear 
dysplasia and it may be anticipated that with longer follow up, the presence of trochlear dysplasia 
may prove to be an important predictor of outcome in our series. 
In our series, the majority of revisions were for progression of disease in other compartments. We did 
not investigate the pattern of disease progression or which compartments were involved. Implant 
loosening and wear were rare events with only 13 known cases out of the 558 implantations.  
Revisions of Avon patello-femoral replacements were consistently to a primary implant, with no need 
for stems or augments in any case. A PFJ replacement can therefore genuinely be considered a less 
invasive option on the arthroplasty ladder. The ease with which patello-femoral replacements, similar 
to other unicompartmental replacements, may be revised has a significant impact upon survivorship. 
Revision rates would be expected to differ between patello-femoral replacements and total knee 
replacements, which have much lower revision rates, but are typically much more complex to revise 
with greater surgical morbidity. The twelve revisions that were for pain with no cause identified should 
in particular be highlighted, as this is not recommended by the authors and we would only recommend 
revision where a specific treatable problem can be identified and managed with further surgical 
intervention. 
There are weaknesses in this study. Follow up was not complete and missing data has the potential to 
affect the findings. However, the rate of follow up was reasonable considering the length of follow- 
up and as such this represents one of the most reliable sources of data on the overall survival of the 
Avon patello-femoral replacement. Pre-operative radiographs were no longer available for many 
cases, especially those cases in the earlier part of the series, and diagnostic codes were relatively 
subjective and were not formally defined. The diagnosis data presented in Figure 5b should be 
interpreted cautiously. The influence of important patient selection factors such as the presence of 
  
dysplasia, or osteophytes in the other compartments, can therefore not be determined. Future studies 
with radiological or cross-sectional imaging of the trochlea may be able to define the relationship 
between pre-operative dysplasia and post-operative outcome.  
 
Conclusion  
This large cohort study of a single implant demonstrates that good results can be obtained with the 
Avon patello-femoral replacement in the long-term. Both surgeon and patient factors are important 
in achieving good post-operative outcomes. Survivorship has improved over time, reflecting the 
contemporary understanding of the most appropriate indications and refinement of surgical 
techniques. Good maintenance of patient outcome scores, acceptable survival and very low rates of 
loosening or wear were observed up to 18 years after the primary operation.  
 
 
 
 
 
  
  
Tables and Figures 
 
Table 1. Reasons for revision. The number of causes totals 108 as there are three cases in which 
both femoral loosening and tibiofemoral progression were recorded by the surgeon. 
 
 
Cause for revision Number 
OA progression 61 
Pain (cause unknown) 12 
Femoral loosening 7 
Button wear 6 
Mal-alignment or mal-sizing* 2 
AVN femoral condyle 2 
Unknown/not recorded 18 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Table 2. Oxford Knee Scores (0-48, 48 the best score) and WOMAC scores (0-100, 0 the best score) 
over the study period, expressed as medians and interquartile ranges (IQR). 
 
 
 Number of 
cases with 
PROMs 
Oxford Knee Score WOMAC 
 Median IQR Median IQR 
Pre-op 524 19 14-25 62 48-70 
1 year 321 35 24.5-42 37 25-52 
2 years 346 35 25-43 35 25-53 
5 years 196 34 22-43 36 23-55 
8 years 131 33 21-39.5 38 25-63 
10 years 125 32 21-40.5 37.5 26.5-60 
12 years 72 32.5 24.5-41.5 43 26.5-56 
15 years 37 35 20-41 35 23-45 
 
 
  
  
Figure 1. Mean age at time of surgery plotted in year groups from the start of the study  
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Figure 2. Estimated proportion of patients unrevised (Kaplan-Meier curve) for the full cohort, with 
95% confidence intervals (shaded) 
 
 
 
 
 
 
 
  
  
Figure 3. Incremental changes (that is, the difference between groups, relative to a reference group) 
in the two-year Oxford Knee Score (OKS) for the two factors that were significant in the linear 
regression analysis a) Age Group and b) Diagnosis. The reference groups were a) patients aged under 
50 and b) those with lateral facet osteoarthritis (OA). 
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